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tumorigenesis, we performed transcriptome profiling of rat 
tumors versus normal pituitary. Adenomas showed overrep-
resentation of genes involved in cell cycle, development, cell 
differentiation/proliferation, and lipid metabolism. Bioinfor-
matic analysis identified downstream targets of the transcrip-
tion factor SF-1 as being up-regulated in rat (and human) 
adenomas. Meta-analyses demonstrated remarkable similari-
ties between gonadotroph adenomas in rats and humans, and 
highlighted common dysregulated genes, several of which 
were not previously implicated in pituitary tumorigenesis. 
Two such genes, CYP11A1 and NUSAP1, were analyzed in 
39 human gonadotroph adenomas by qRT-PCR and found 
to be up-regulated in 77 and 95 % of cases, respectively. 
Immunohistochemistry detected high P450scc (encoded by 
CYP11A1) and NuSAP expression in 18 human gonado-
troph tumors. In vitro studies demonstrated for the first time 
that Cyp11a1 is a target of SF-1 in gonadotroph cells and 
Abstract Gonadotroph adenomas comprise 15–40 % of all 
pituitary tumors, are usually non-functioning and are often 
large and invasive at presentation. Surgery is the first-choice 
treatment, but complete resection is not always achieved, 
leading to high recurrence rates. As gonadotroph adenomas 
poorly respond to conventional pharmacological therapies, 
novel treatment strategies are needed. Their identification 
has been hampered by our incomplete understanding of the 
molecular pathogenesis of these tumors. Recently, we dem-
onstrated that MENX-affected rats develop gonadotroph 
adenomas closely resembling their human counterparts. To 
discover new genes/pathways involved in gonadotroph cells 
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promotes proliferation/survival of rat pituitary adenoma pri-
mary cells and cell lines. Our studies reveal clues about the 
molecular mechanisms driving rat and human gonadotroph 
adenomas development, and may help identify previously 
unexplored biomarkers for clinical use.
Keywords Pituitary gonadotroph adenoma · 
Transcriptome analysis · MENX model · CYP11A1 · 
NUSAP1
Introduction
Clinically non-functioning adenomas of the pituitary gland 
account for about 30 % of all adenomas. About 80 % of 
them belong to the gonadotroph lineage. They are usually 
diagnosed when signs and symptoms of mass effects occur, 
and about 40 % of them extend to the cavernous sinus and, 
less commonly, invade the sellar floor, making their resec-
tion and post-operative radiotherapy challenging [14, 34]. 
In addition, they are usually resistant to pharmacological 
treatment with somatostatin analogs and dopamine ago-
nists. Chemotherapy has been reserved as salvage therapy 
in aggressive cases although the results have often been 
disappointing [34]. Novel therapeutic approaches are there-
fore needed for these tumors.
A prerequisite to identify novel therapeutic targets for 
human tumors is a good understanding of the pathogenetic 
mechanisms. The molecular mechanisms underlying the 
development of PAs in general, and of gonadotroph adeno-
mas in particular, have only been incompletely unraveled 
and this is in part due to the limited availability of suitable 
animal models and by the fact that those available are not 
always representative of human adenomas [27].
We have recently identified a multiple endocrine neo-
plasia syndrome occurring in a Sprague–Dawley-derived 
rat strain (named MENX) characterized by the occurrence 
of spontaneous PAs with complete penetrance. MENX is 
caused by a biallelic loss-of-function mutation in Cdkn1b, 
encoding the cell cycle inhibitor p27, which results in a 
highly unstable protein [29, 33]. MENX-associated PAs 
are histologically and ultrastructurally remarkably similar 
to human gonadotroph adenomas. They also show high 
mitotic activity and elevated Ki67 labeling index [26]. Pri-
mary cells derived from these tumors are a suitable model 
for pharmacological studies of PAs [24].
To elucidate the mechanisms associated with the devel-
opment of human gonadotroph adenomas we exploited the 
MENX model and performed whole genome transcriptome 
analysis of the rat tumors and of normal pituitary tissues of 
wild-type animals. With this approach, we have identified 
genes differentially expressed in rat PAs that had been pre-
viously found dysregulated in human adenomas by array 
analysis, but not yet further validated. We here show that 
two such genes (i.e. CYP11A1 and NUSAP1) are highly 
expressed at both mRNA and protein level in human gon-
adotropinomas and may represent novel biomarkers of 
these tumors. In vitro functional assays demonstrated for 
the first time that the high expression of Cyp11a1 promotes 
proliferation/survival of PA cells (gonadotroph- and soma-
totroph-derived), thereby supporting a role for this gene in 
pituitary tumorigenesis. We also determined that Cyp11a1 
expression is regulated by the steroidogenic transcription 
factor SF-1 in gonadotroph cells. Noteworthy, in addition 
to NUSAP1, other genes involved in mitosis were found 
overexpressed in both rat and human PAs by meta-analysis. 
If further validated, these genes may represent novel poten-
tial targets for the therapy of gonadotropinomas.
Materials and methods
Human pituitary tissue samples
Pituitary adenoma samples were obtained from patients 
at Imperial College and the University of Tübingen at the 
time of transsphenoidal surgery. All patients consented for 
research and appropriate ethical approval for the study was 
obtained. Fragments of the specimens that were not used 
for diagnostic assessment were snap-frozen at −80 °C. 
Gonadotroph tumors were defined as demonstrating posi-
tive immunostaining for LHβ, FSHβ or αGSU in >5–10 % 
of cells. Extension to the cavernous sinus and invasive-
ness of the sellar floor were identified at preoperative mag-
netic resonance imaging (MRI). The modified Hardy cri-
teria were applied [18]. Post-mortem samples of normal 
adenohypophysis used for immunohistochemistry (IHC) 
were obtained from Imperial College. Autopsies were per-
formed within 2–18 h from death and were formalin-fixed 
and routinely processed to paraffin embedding. Consent 
for research use of this tissue was obtained from families. 
RNA of normal pituitary tissues was purchased from Bio-
Chain Inc (Hayward, CA, USA).
Rat pituitary tissue samples
MENX-affected rats develop multifocal pituitary adenomas 
in the anterior lobe of the gland. Based on hormone expres-
sion by immunohistochemistry we could establish that 
these tumors mainly derive from gonadotroph cells [26]. 
The lesions become histologically detectable at 4 months of 
age and progress to become large, mature tumors that efface 
the gland at 7–8 months. The number of cells expressing 
LHβ or FSHβ decreases with tumor progression and is neg-
ligible in the largest adenomas, while tumors remain posi-
tive for the common gonadotropin alpha subunit (αGSU). 
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Rat adenomas show mitotic activity and high Ki67 labeling 
(average 8 % at 7–8 months), thus resembling aggressive 
pituitary adenomas. Approximately 10–17 % of the pitui-
tary lesions contain cells expressing growth hormone (GH) 
or prolactin (PRL) [26]. The pituitary glands used for RNA 
extraction (upon microdissection) derived from rats aged 
7–8 months having large tumors approximately 1–2 mm in 
size.
RNA isolation and microarray preparation
Rat RNA was extracted from macrodissected pituitary tis-
sues and processed for array analysis as reported [30]. 
Amplified cDNA (2 μg) was hybridized on Affymetrix 
Rat Gene 1.0 ST arrays (Santa Clara, CA, USA) contain-
ing about 26 k gene-level probe sets. Staining and scanning 
was done according to the Affymetrix expression protocol. 
RNA was extracted from frozen human pituitary tumor 
samples following standard protocols [30].
Biostatistical and bioinformatic analysis
Expression console (Affymetrix) was used for quality con-
trol and to obtain annotated normalized RMA gene-level 
data (standard settings including median polish and sketch-
quantile normalization). Statistical analyses and heat maps 
were generated in CARMAweb [36]. Genewise testing for 
differential expression was done employing t test and Ben-
jamini-Hochberg multiple testing correction (FDR < 5 %). 
Genes with fold-changes >2× were further analyzed using 
GePS software (Genomatix Software GmbH, Munich, 
Germany). Signaling pathways containing, or regulated 
by, differentially expressed genes were identified using 
the Ingenuity Pathway Analysis (IPA) library of canonical 
pathways. Array data were submitted to Gene Expression 
Omnibus (GSE23207). The comparison of rat and human 
datasets was done in Venny (http://bioinfogp.cnb.csic.es/
tools/venny/index.html) based on the match of human 
genes to rat probe set IDs via rat Entrez IDs provided by 
Affymetrix. Human Entrez IDs of regulated genes were 
matched to rat Entrez IDs mainly based on the NCBI 
homologene database, supplemented with information pro-
vided by Ingenuity pathway software. Human datasets were 
taken from publications: Morris et al. [32], 1,723 probe sets 
with fold-changes >1.5×; Moreno et al. [31], Supplemen-
tary Table 2,297 probe sets with fold-changes >2×) or cal-
culated from.cel files; Michaelis et al. [28], Acc. Number 
GSE26966, analysis as described above, 3,558 probe sets 
with ratios >2×. All human datasets were done with Affy-
metrix arrays and human Entrez IDs of regulated probe 
sets were taken from annotations provided by Affymetrix. 
For pairwise comparisons of rat and human datasets, probe 
set based gene lists from the Venn diagram were further 
processed: for redundant entries only the entry with the 
highest ratio in rat was kept, and datasets were filtered for 
the same direction of regulation in rat and human datasets.
Cell culture, treatments and assays
GH3 and Y1 cells were purchased from the ATCC and 
grown in DMEM supplemented with 10 % (v/v) FBS 
and 1 % (v/v) penicillin–streptomycin. The murine gon-
adotroph cell line LβT2 was kindly provided by P. Mel-
lon (University of California, San Diego, USA) and was 
grown in DMEM + GlutaMAX™-I plus 4.5 g/l d-glucose 
and pyruvate with 10 % (v/v) FBS and 1 % (v/v) penicil-
lin–streptomycin. Primary pituitary tumor cells were iso-
lated from mutant rat pituitaries and grown as previously 
described [24]. Media, serum and supplements were from 
Gibco/Invitrogen (Karlsruhe, Germany). Transfection with 
siRNA oligos was performed as previously reported [24]. 
For infections, GH3 and primary tumor cells were plated 
on 96-well plates and 24 h later cells were infected by len-
tiviral vectors expressing the green fluorescence protein 
(GFP) or GFP and shRNA against Cyp11a1. Virus pro-
duction and lentiviral infection were performed accord-
ing to previous protocols [2]. WST-1 colorimetric assay 
(Roche, Mannheim, Germany) for cell viability was per-
formed 72 h after infection according to the manufacturer’s 
recommendations.
Apoptosis was measured by assessing the activity of cas-
pase-3/7 using Caspase-Glo® 3/7 Assay kit (Promega, Man-
nheim, Germany). Primary cells or transfected GH3 cells 
were plated in 96-well plates and 36 h later were infected 
with sh-Cyp11a1 or mock GFP lentiviral vectors. Forty-
eight h after treatment, caspase-3/7 enzymatic activity 
was assessed with a proluminescent caspase-3/7 substrate 
which contains the tetrapeptide sequence DEVD. Lumines-
cence was measured using a luminometer (Berthold, Bad 
Wildbad, Germany).
For treatment with ethyl 2-[[2-[2-[(2,3-dihydro-1,4-ben-
zodioxin-6-yl)amino]-2-oxoethyl]-1,2-dihydro-1-oxo-
5-isoquinolinyl] (IsoQ) (Tocris Bioscience, Bristol, UK), 
2.5 × 104 primary rat pituitary cells (2.5 × 104 cells/well) 
or LβT2 cells (1 × 104 cells/well) were seeded into 96-well 
plates and allowed to settle for 36 h. IsoQ was dissolved 
in DMSO and serial dilutions (10 μM–10 nM) were pre-
pared in culture medium. Treated cells were incubated with 
IsoQ for 24 and 48 h, while control cells with 0.01 % (v/v) 
DMSO. Cell viability was assessed using the WST-1 assay 
as above.
Quantitative TaqMan RT-PCR
Quantititative RT-PCR was performed using TaqMan 
inventoried primers and probes for the genes reported in 
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the article and for the rat beta 2-microglobulin gene, mouse 
beta 2-microglobulin gene or human TBP gene as inter-
nal controls (Applied Biosystem, CA, USA). RNA was 
extracted and TaqMan assays were set up as previously 
reported [30].
RNA interference
The specific Cyp11a1 shRNA sequence was cloned into 
the pSUPER lentiviral vector. The sequence of the com-
plementary oligonucleotides is: sh-Cyp11a1 Fw GATCC 
GGATGTTGGAGGAGATCGTTTCAAGAGAAC 




Immunohistochemistry (IHC) staining was performed on 
an automated immunostainer (Ventana Medical Systems, 
Tucson, AZ, USA) according to the manufacturer’s pro-
tocols with minor modifications, as previously described 
[30]. Primary antibodies were raised against Ass1 (Sigma, 
Louis, MO, USA); Ki-67 (Clone B56, Dako, Hamburg, 
Germany); rat P450scc (Abcam, Abcam, Cambridge, 
UK); human P450scc (Santacruz, Heidelberg, Germany); 
NuSAP (Proteintech, Chicago, IL, USA). Antibodies were 
diluted in Dako REALTM antibody diluent (Dako). The 
supersensitive detection system (BioGenex, Munich, Ger-
many) was used and the immunoreaction was developed in 
the diamino-benzidine (DAB) supplied with the kit (Vector 
lab, Burlingame, CA). Positive controls were included in 
each batch. To score the P450scc staining, both the inten-
sity of the staining and the number of positive tumor cells 
were taken into consideration. For number of positive cells, 
we used a score: 0 = 0 % (or <1 %) positive cells; 1 = up 
to 25 % positive cells; 2 = up to 50 %; 3 = up to 75 %; 
4 = up to 100 %. For staining intensity, a 4-scaled scor-
ing system was used: 0 = negative, 1 = weak, 2 = moder-
ate, 3 = strong. These values were then multiplied to obtain 
‘immunoreactivity scores’ (IRS). Ki67 and NuSAP nuclear 
immunoreactivity was determined semiquantitatively and 
was indicated as the percent of positive cells against all 
neoplastic cells in the section examined (Labeling Index, 
LI). Images were recorded using a Hitachi camera HW/
C20 installed in a Zeiss Axioplan microscope with Intelli-
cam software (Carl Zeiss MicroImaging GmbH, Gottingen, 
Germany).
For immunofluorescence (IF), we used the primary 
antibodies used for IHC and secondary anti-mouse Alexa 
Fluor® 555 Conjugate (Cell Signaling) or anti-rabbit FITC-
conjugated (Invitrogen, Darmstadt, Germany) antibod-
ies as reported [26]. Sections were then analyzed with a 
Zeiss Axiovert 200 epifluorescence microscope including 
Apotome unit (Carl Zeiss MicroImaging GmbH).
Statistical analysis
Results of the cell viability assays are shown as the mean 
of values obtained in independent experiments ± SEM 
(standard error of the mean). A paired two-tailed Student’s 
t test was used to detect significance between two series 
of data and P value (P) < 0.05 was considered statistically 
significant.
Results
Genetic signature of MENX-associated pituitary adenomas
In order to unravel the genetic changes associated with 
pituitary adenoma (PA) formation, we performed whole 
genome transcriptome analysis of 16 individual pituitary 
lesions from 11 adult MENX mutant rats (8 months of 
age) and compared them with 5 normal pituitaries. Using 
a >twofold-change cut-off for gene expression changes, 
487 probe sets appeared up-regulated in adenomas versus 
normal wild-type gland, and 400 were down-regulated 
(Supplementary Fig. 1 and Dataset 1). The relative high 
number of differentially expressed transcripts is not unex-
pected since normal pituitary is composed of multiple 
cell types of which only 10–20 % are gonadotroph cells. 
Gene ontology (GO) term enrichment analysis showed 
that genes related to cell cycle (P = 9.85E−09), develop-
ment (P = 1.2E−06), cell differentiation (P = 1.36E−06), 
cell proliferation (P = 2.53E−07), and lipid metabolism 
(P = 9.43E−04) are overrepresented in our dataset (ratios 
>twofold, Table 1). Genes encoding proteins involved 
in cell cycle regulation and especially in mitosis such as 
Aurka, Bub1, Bub1b, Ccna1, Ccnb1, Ccnb2, Ccne1, Cdc2, 
Cdc20, Cdkn3, Kif4, Kif11, Nusap1, Prc1, as well as genes 
involved in pituitary development or adenohypophyseal 
cell differentiation, such as Dax-1/Nr0b1, Egr1, Fgfr2, 
Neurod1, Notch2, Nr5a1, Pou1f1, Tbx19 [6, 10, 23] were 
differentially expressed in rat PAs (Table 1). Array data 
mining found that genes such as Ccnb1, Igfbp3, Nusap1, 
Pttg1, Racgap1, Top2a, Tpx2, which are associated with 
the aggressive behaviour of various human tumors, includ-
ing PAs, and proto-oncogenes such as Ect2, Kit, Kras, Lyn, 
Ret are up-regulated in rat adenomas [12, 15, 42, 43]. This 
result is in agreement with the elevated proliferative activ-
ity of the tumors [26]. Interestingly, also genes belonging 
to the category “lipid metabolic process” were significantly 
overrepresented in the rat adenomas, and several of them 
are known targets of the transcription factor steroidogenic 
factor 1 (SF-1) (see below).
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Genes encoding pituitary hormones were down-regu-
lated in rat adenomas, with the exception of Cga encoding 
the common alpha subunit of the gonadotropins (αGSU), 
which was highly expressed in all adenomas (Supplemen-
tary Fig. 1). These results are in keeping with previous 
immunohistochemical stainings showing that the large, 
older rat pituitary lesions do not express any hormone sub-
unit except αGSU [26].
Transcription factor analysis using Ingenuity Pathway 
Analysis (IPA) predicted the activation of several upstream 
transcription factors, including Nr5a1 (z-score = +2.34; 
P = 5E−08) encoding SF-1 (Supplementary Table 1). The 
genes encoding the gonadotropin hormone subunits LHβ 
and FSHβ, which are transcriptionally regulated by SF-1 
in gonadotroph cells, are down-regulated in the large rat 
tumors, as mentioned above. In contrast, several down-
stream targets of SF-1 were found highly expressed in the 
adenomas. While the mRNA level Nr5a1 was up-regulated 
2.7-fold in the adenomas (Dataset 1), its downstream tar-
gets were overexpressed up to 23-fold in the tumors, 
including Angpt2, Cyp11a1, Cyp11b1, Cyp11b2, Giot1, 
Gnrhr, Nos1, Nr0b1/Dax1, Nr0b2, Scarb1. Also Fgf13 and 
Col18a1 were up-regulated, as reported in adrenal cancer 
cells [8], and so was Cited2, encoding for a co-activator of 
SF-1 during adrenal development [40]. Altogether, these 
data suggest that the activity of SF-1 is enhanced in rat PAs 
(Supplementary Fig. 2a). Further support to the activation 
of SF-1 in the rat tumors came from the validation of 
Cyp11b1 and Cyp11b2 overexpression in independent 
adenoma samples (Supplementary Fig. 2b). Several of the 
SF-1 targets mentioned above play a physiological role in 
the synthesis or transport of steroid hormones in steroido-
genic tissues and have not so far been implicated in adeno-
hypophyseal tumorigenesis.
Real-time quantitative RT-PCR (qRT-PCR) for 9 
selected overexpressed genes was performed on 11 addi-
tional individual pituitary adenomas to validate the array 
data (Fig. 1a). These tumors were compared with five pitui-
taries from wild-type rats. Nr5a1 (Sf-1) and Cga (αGSU) 
were included as controls because the encoded proteins are 
expressed in these tumors [26], while the other transcripts 
were chosen because they have interesting functions and 
they span a broad range of increased fold-changes, from 
~3-fold to >20-fold. The results confirmed the up-regula-
tion of these genes in rat PAs, with Cdkn1c (p57) showing 
a trend toward higher levels in the tumors versus normal 
pituitary which did not reach the statistical significance 
(Fig. 1a). qRT-PCR also confirmed the down-regulation of 
Pomc, Lhb, Fshb in rat adenomas (Fig. 1b).
The differential expression of selected genes was fur-
ther validated with immunohistochemistry (IHC) and 
immunofluorescence (IF). Stainings for argininosuccinate 
synthetase 1 (Ass1), NuSAP, Cyclin E, P450scc (encoded 
by Cyp11a1) showed higher Ass1 and P450scc levels in 
Table 1  Enriched GO categories by GePS software from Genomatix





Enriched terms within the up-regulated genes
 Cell cycle GO: 0007049 9.85E−09 42/16 667 Aurka, Bmp7, Bub1, Bublb, Ccnbl, Ccnb2, Cdc2, 
Cdc20, Cdknla, Cdkn2c, Cdkn3, Cenpf, Cited2, Id2, 
Nusapl, Pttgl
 Developmental  
process
GO: 0032502 1.20E−06 98/62 2,597 Angpt2, Ass1, Bmp7, Cdkn2c, Cited2, Cyp11a1, 
Fgfr2, Id2, Igfbp3, Igfbp7, Lyn, Neurod1, Nos1, 
Nr0b2, Nr0b1, Nr5a1, Ret, Sox11
 Cell differentiation GO: 0030154 1.36E−06 63/34 1,431 Angpt2, Apoe, Ar, Bag1, Bmp7, Ccnb1, Cdc2, Cdkn2c, 
Cenpf, Cited2, Cyp11a1, Fgfr2, Id2, Igfbp3, Kit, 
Kras, Lyn, Neurod1, Neurod4, Nr0b1, Nr5a1,  
Racgap1, Ret, Sox11, Top2a, Tshr, Vegfa
 Cell proliferation GO: 0008283 2.53E−07 45/20 832 Apoe, Ar, Bub1, Ccna2, Ccnb1, Cdc2, Cdc20, Cdkn1a, 
Cdkn1c, Cdkn2c, Cenpf, Fgfr2, Gnrhr, Id2, Igfbp3, 
Kit, Kras, Lyn, Pttg1, Racgap1, Scarb1, Sox11, Tac1, 
Vegfa
 Lipid metabolic  
process
GO: 0006629 9.43E−04 33/19 772 Apoe, Apof, Cyp1b1, Cyp11a1, Cyp11b1, Cyp11b2, 
Fdxr, Nr0b1, Scarbl
Enriched terms within the down-regulated genes
 Developmental  
process
GO: 0032502 7.73E−10 69/34 2,597 Egr1, Notch2, Nr4a3, Sema3e, Dlk1, Angptl, Nr4a2, 
Ghrhr, Adcyap1r1, Pou1f1, Tbx19
 Negative  
regulation of  
cell proliferation
GO: 0008285 9.29E−03 9/4 271 Nfib, Notch2, Gjb6, Wfdd, Rbp4, Gpc3, Cdk6, Msx1, 
Slit2
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tumors compared with non-tumorous pituitary tissue of 
mutant rats or wild-type rat pituitaries (Fig. 1c). Similarly, 
NuSAP- and CyclinE-positive cells were found in higher 
number in adenomas compared with surrounding non-
tumorous gland, or with normal pituitaries (Fig. 1c).
Dysregulated pathways and genes previously associated 
with human pituitary tumors
Some of the pathways identified as dysregulated in rat PAs 
by the IPA software have also been implicated in human 
PAs by proteomics profiling, and include cell cycle, lipid 
metabolism and endocrine system development [45]. In 
addition, the homologues of several genes up-regulated in 
the rat tumors had also been already implicated in human 
non-functioning/gonadotroph PAs. Examples are ECT2, 
NEUROD1, PTTG1, VEGFA and the oncogene c-fos [22, 
25, 31, 32]. NOS1 and DAX1, regulated by and/or regulat-
ing the transcription factor SF-1, are highly expressed in 
human gonadotroph adenomas [20, 39]. Androgen receptor 
(AR) is expressed in 74 % of gonadotropinomas [37], and 
DLK1 is silenced in non-functioning adenomas, while it is 
highly expressed in functional adenomas [1].
Studies comparing the transcriptome of human gonado-
troph adenomas with that of normal pituitary tissues [1, 9, 
11, 28, 31] or of non-invasive versus invasive gonadotroph 
adenomas [12, 19] have been performed. We therefore com-
pared our Dataset 1 with the available lists of significantly 
differentially expressed genes in human non-functioning/
gonadotroph adenomas. Examples of concordantly dysregu-
lated genes in both species are reported in Supplementary 
Table 2. Remarkably, the degree of overlap of genes dif-
ferentially expressed among different human sample sets is 
similar to the overlap between rat and human datasets, as 
Fig. 1  Validation of selected genes by qRT-PCR and by IHC on rat 
PA tissues. a, b RNA was extracted from 11 macrodissected pituitary 
tumors of adult mutant rats and from five normal pituitaries of wild-
type (wt/wt) rats. qRT-PCR was performed using TaqMan primer and 
probe sets specific to a rat genes up-regulated by array analysis: Ass1, 
Bmp7, p57, NeuroD1, Lyn, Id2, Cpy11a1, Pttg, Nusap, Nr5a1 and b 
rat genes down-regulated by array analysis: Lhβ, Fshβ, Pomc, Cga 
(αGSU). The relative mRNA expression level of the target genes was 
normalized for input RNA using the housekeeping β2-microglobulin 
gene and a calibrator RNA always run in parallel and was calculated 
with the 2−ΔΔCt formula. The obtained relative value was normalized 
against the average level in normal pituitary, arbitrarily set to 1. The 
boundary of the box closest to zero indicates the 25th percentile, the 
line within the box marks the median, and the boundary of the box 
farthest from zero indicates the 75th percentile. Error bars above 
and below the box indicate the 99th and 1th percentiles. *P < 0.05, 
**P < 0.001. c Formalin-fixed, paraffin-embedded (FFPE) pituitaries 
from adult wild-type (WT) (left) and mutant (MUT) (right) rats were 
used. IHC was performed using antibodies against ASS1 and NuSAP 
and counterstained with hematoxylin. Immunofluorescence was per-
formed with antibodies against P450scc or Cyclin E and nuclei were 
counterstained with DAPI. T tumor area, N normal adjacent area. 
Original magnification: ×200; insets: ×400
143Acta Neuropathol (2013) 126:137–150 
1 3
estimated using Venn diagrams (Fig. 2). The 10 genes dif-
ferentially expressed in all the datasets we compared are: 
Ptprk, Atp8a1, Lgals3, Nr4a2, Pon3, Fos, Angpt1, Amigo2, 
Rcan2, Maob (for details, please refer to “Materials and 
methods”). We found several common dysregulated genes 
in the rat tumors and in the dataset recently published by 
Michaelis et al. [28] analyzing 14 human gonadotroph 
adenomas. Among the genes dysregulated in both rat and 
human adenomas, we found genes associated with pituitary 
function or pituitary tumorigenesis and mentioned earlier in 
the article, such as AR, CCNB1, DLK1, ECT2, FOS, NEU-
ROD1, NR0B1/DAX1, VEGF. Genes encoding transcrip-
tion factors and hormones important in other pituitary cell 
lineages (i.e. POU1F1/PIT-1, TBX19, GH, PRL, POMC) 
are down-regulated in rat and human gonadotroph-derived 
adenomas, as expected. BAG1, coding for an anti-apoptotic 
protein, was found overexpressed in human non-function-
ing PAs by array analysis [32], and is also up-regulated in 
MENX-associated adenomas. Similarly to the rat tumors, 
several downstream targets of SF-1 were found to be highly 
expressed in human gonadotroph adenomas by array analy-
sis (Supplementary Fig. 3). Interestingly, several genes dys-
regulated in both human and rat array datasets, although not 
yet evaluated in PAs, have been shown to play a role in other 
human malignancies, such as BUB1, BUB1B, GALNT12, 
GPC3, HMMR, KIF4, NR4A3, NUSAP1, PDE4B, PRC1 
and thus warrant follow-up studies.
CYP11A1 and NUSAP1 are overexpressed in human PAs
Among the genes overexpressed in the rat pituitary ade-
nomas, predicted to be up-regulated in at least 2 of the 3 
human expression array studies by data mining (Supple-
mentary Table 2, in bold), and never before associated with 
pituitary adenomas, are Cyp11a1 and Nusap1. Thus, these 
two genes were selected for further analyses. Cyp11a1 
encodes P450scc, the mitochondrial enzyme that catalyzes 
the conversion of cholesterol to pregnenolone in steroido-
genic tissues. Nusap1 encodes a protein that plays a role in 
spindle microtubule organization and is necessary for cell 
division [35]. To verify whether these genes are truly up-
regulated in human gonadotroph adenomas, we performed 
qRT-PCR in a series of 39 samples. NR5A1 and NEUROD1 
were also included in the analysis as they are expected to 
be up-regulated in these tumors. We found that CYP11A1 
was up-regulated in 77 % (27 out of 35) and NUSAP1 in 
95 % (37 out of 39) of the human PAs (Fig. 3a). NR5A1 
and NEUROD1 were overexpressed in 82 % of the cases.
To determine whether gene up-regulation translates into 
higher levels of the encoded protein, we obtained forma-
lin-fixed, paraffin-embedded (FFPE) tissue blocks from 
18 of the adenomas analyzed by qRT-PCR, and stained 
them for P450scc and NuSAP. Normal anterior pituitary 
cells had only weak cytoplasmic positivity for P450scc in 
sparse hypophyseal cells, while P450scc staining was more 
intense, although often uneven, in adenomas (Fig. 3b). 
Immunoreactivity score (IRS) were calculated and showed 
that 13 of 18 cases (72 %) had a IRS ≥6, indicating moder-
ate to strong staining in up to 75 % of the tumor cells, and 
5 cases (28 %) showed weaker staining (IRS ≤4) (Fig. 3c). 
Of the human gonadotropinomas used for IHC, 9 were 
invasive and 8 non-invasive. No significant difference in the 
degree of positivity for P450scc was observed between the 
two groups of tumors.
We also performed IHC to detect NuSAP expression 
and we could detect tumor cells having a strong, nuclear 
staining in every human PA sample (Fig. 3b). Being 
NuSAP associated with mitosis, we determined the rela-
tionship between its expression and that of the Ki67 anti-
gen, an established marker of cell division. Quantification 
of the IHC results demonstrated that Ki-67-positive cells 
were more numerous than NuSAP-positive cells (Fig. 3c). 
NuSAP-positive pituitary tumor cells always co-expressed 
Ki-67 (Fig. 4a). Co-expression of the two markers was also 
seen in rat PAs, which have elevated proliferation rates 
(Fig. 4a) [26]. A good correlation between the Labeling 
Index (LI) of NuSAP and of Ki-67 was seen in the human 
tumor tissue samples (R2 = 0.8131) (Fig. 4b).
Cyp11a1 plays a pro-proliferative role in tumorigenesis
We have established that Cyp11a1 is highly expressed in 
rat and human gonadotroph tumors at mRNA and protein 
levels. To clarify the role of this gene in tumorigenesis, 
we first used Y1 cancer cells derived from a steroidogenic 
Fig. 2  Overlap of differentially expressed genes. Venn diagram dis-
playing the overlap among lists of differentially expressed genes from 
gene expression studies in human gonadotroph/non-functioning PAs 
[28, 31, 32] and rat PAs (Dataset 1). For details, see “Materials and 
methods”
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tissue and expressing Cyp11a1 at high level. siRNA-medi-
ated knock-down of Cyp11a1 reduced the ability of Y1 
cells to proliferate when compared with cells transfected 
with scrambled siRNA oligos (Supplementary Fig. 4b). 
Efficient knock-down of the Cyp11a1 gene was verified by 
qRT-PCR (Supplementary Fig. 4a). Encouraged by these 
findings we pursued the role of Cyp11a1 overexpression 
in pituitary tumorigenesis. We used somatotroph adenoma-
derived GH3 cells, which express relatively high levels of 
Cyp11a1 (Supplementary Fig. 5), to evaluate the effect of 
modulating gene expression on pituitary tumor cell pro-
liferation. We found that siRNA-mediated silencing of 
Cyp11a1 reduced GH3 cells proliferation, while scrambled 
siRNA oligos elicited no effect (Supplementary Fig. 4c, d).
qRT-PCR showed that rat primary PA cells maintain 
the high Cyp11a1 expression level observed in the tumor 
tissues from which they derive (Supplementary Fig. 5), and 
thus represent a suitable model for analyzing the effect of 
gene knock-down. As these cells were difficult to transfect, 
we generated a lentiviral vector expressing both a small 
hairpin (sh) RNA molecule directed against rat Cyp11a1 
and the green fluorescent protein (GFP) to monitor infec-
tion efficiency (ca. 80 %, data not shown). Two RNA 
sequences were tested but only one gave a consistent and 
robust gene down-regulation and was then used on fur-
ther experiments (data not shown). The sh-Cyp11a1 lenti-
viral vector was first tested in GH3 cells (Fig. 5a), where 
it caused a very strong decrease in Cyp11a1 expression 
(Fig. 5b, c) and, concomitantly, a reduction in cell prolif-
eration when compared with mock infected cells (GFP) 
(Fig. 5d). In growth curve experiments, viral-mediated 
Cyp11a1 knock-down decreased the growth rate of GH3 
Fig. 3  Overexpression of CYP11A1 and NUSAP1 and their encoded 
proteins in human gonadotroph tumors. a RNA was extracted from 
frozen pituitary tumors obtained after transsphenoidal surgery. qRT-
PCR was performed using TaqMan primer and probe sets specific 
to human NR5A1, CYP11A1, NUSAP1 and NEUROD1. The relative 
mRNA expression level of the target genes was normalized for input 
RNA using human TBP gene expression (housekeeping gene) and a 
calibrator human brain RNA always run in parallel and was calcu-
lated with the 2−ΔΔCt formula. The obtained relative value was nor-
malized against the average expression of normal pituitary arbitrarily 
set to 1. The boundary of the box closest to zero indicates the 25th 
percentile, the line within the box marks the median, and the bound-
ary of the box farthest from zero indicates the 75th percentile. Error 
bars above and below the box indicate the 99th and 1th percentiles. 
b Human normal pituitary (top) and gonadotroph adenoma samples 
were used. IHC was performed using antibodies against P450scc 
(left) or against NuSAP (right) and counterstained with hematoxylin. 
Original magnification: ×200; insets: ×400. c Scoring of the expres-
sion of NuSAP, Ki-67 and P450scc in a series of human gonadotroph 
adenomas
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Fig. 4  Expression of Ki-67 
and NuSAP in rat and human 
pituitary adenoma cells.  
a Example of immunofluorescent 
staining with antibodies against 
Ki-67 (red) and NuSAP (green) 
performed on FFPE pituitary 
tumor tissues from a MENX 
rat (MENX) and from a patient 
with gonadotroph adenoma 
(Human). Nuclei were coun-
terstained with DAPI. Only the 
tumor area is shown. Original 
magnification: ×100. b Correla-
tion between NuSAP and Ki-67 
labeling index (LI) in 12 human 
gonadotroph adenoma samples
Fig. 5  Effect of Cyp11a1 on tumor cell proliferation. a Infection of 
GH3 cells with lentiviral vectors expressing shCyp11a1-GFP or GFP 
only (MOCK). b GH3 cells were infected with the lentiviral vec-
tors as in “a” and the level of Cyp11a1 was analyzed by qRT-PCR 
72 h later. c In samples parallel to “b”, proteins were extracted, and 
Western blotting was performed to monitor Cyp11a1 expression. The 
ratios of the band intensities for P450scc versus α-tubulin, normal-
ized against the ratio in the MOCK control (ratio = 1), is indicated. 
d In samples parallel to “b”, cell proliferation was assessed 72 h after 
infection using the WST-1 assay. Data were analyzed independently 
with six replicates each and were expressed as the mean ± SEM. e 
Growth curve of GH3 cells infected with lentiviral vectors express-
ing shCyp11a1-GFP or GFP only (MOCK). Cells were trypsinized, 
stained with Trypan Blue and viable cells were counted. Values are 
the mean of 3 independent experiments ± SD. f In samples parallel 
to “d”, the expression of p21 was assessed by qRT-PCR as indicated 
in the legend of Fig. 1, and is reported relative to the expression 
level in mock-transfected cells arbitrarily set to 1. g In samples par-
allel to “d”, caspase 3/7 activity was measured to monitor apoptosis 
72 h post-infection. Data were analyzed independently with six rep-
licates each and were expressed as the mean ± SEM. **P < 0.01, 
***P < 0.001, versus MOCK
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cells, while infection with the mock vector had not effect 
on cell growth (Fig. 5e).
To determine what caused the reduction in the prolifera-
tion capacity of GH3 cells, we checked for the induction of 
cell cycle inhibitors following Cyp11a1 gene knock-down. 
We determined the level of expression of p16, p18 and p21 
after infection by qRT-PCR and we found that while the 
amount of p16 and p18 transcripts does not change (data 
not shown), p21 expression increases significantly upon 
reduction of Cyp11a1 levels (Fig. 5f). We also assessed 
caspase-3/7 activity as a measure of apoptosis in GH3 cells 
infected with GFP or with sh-Cyp11a1. Caspase-3/7 activ-
ity is higher in cells infected by sh-Cyp11a1 compared with 
mock infected cells, suggesting that this process might also 
explain part of the reduced cell growth (Fig. 5g). We then 
went back to our original model (MENX rats) and estab-
lished primary PA cultures from three independent mutant 
rats. Cells were infected with sh-Cyp11a1 vector, or with 
the mock GFP vector (Fig. 6a) and cell viability was meas-
ured. Upon infection of the primary cells with sh-Cyp11a1 
vector, but not with mock vector, we observed a reduc-
tion in Cyp11a1 expression (Fig. 6b), which was accom-
panied by a decrease in cell viability (−30 % versus con-
trol GFP) (Fig. 6c). Similarly to what we observed in GH3 
cells, also in primary rat PA cells there was an increase in 
both p21 expression and caspase-3/7 activity, although less 
pronounced than in GH3 cells (Fig. 6d, e). In conclusion, 
high expression of Cyp11a1 associates with increased pro-
liferation and survival not only in adrenocortical carcinoma 
cells (Y1), but also in rat pituitary tumor cells from differ-
ent lineages (somatotroph and gonadotroph).
Rat PA cells express both Nr5a1 and Cyp11a1 and, 
noteworthy, in these cells SF-1 and P450scc co-localize, 
as determined by dual co-immunofluorescence (Fig. 7a). 
SF-1 regulates Cyp11a1 transcription in steroidogenic cells 
but whether it also does so in adenohypophyseal cells is 
not known. Therefore, we silenced Nr5a1 expression by 
means of siRNA oligos in gonadotroph LβT2 cells and 
then assessed the level of Cyp11a1 mRNA by qRT-PCR. 
As experimental control, we used again Y1 adrenocortical 
cancer cells, where Nr5a1 gene down-regulation caused a 
reduction of Cyp11a1 mRNA expression (Supplementary 
Fig. 6). We observed that knock-down of Nr5a1 in LβT2 
cells, as demonstrated by western blotting (Fig. 7b), asso-
ciates with a decrease in Cyp11a1 expression (Fig. 7c). 
To further confirm that SF-1 transcriptional activity plays 
a role in regulating Cyp11a1 expression in these cells, 
we treated LβT2 cells with a small molecule inhibitor of 
SF-1, isoquinolinone (IsoQ) [8]. This compound caused a 
significant dose-dependent reduction of Cyp11a1 expres-
sion (Fig. 7d). Similar results were also obtained expos-
ing rat primary PA cells (with high endogenous levels of 
Fig. 6  Effect of Cyp11a1 on primary pituitary tumor cell prolifera-
tion. a Infection of rat primary pituitary tumor cells with lentiviral 
vectors expressing shCyp11a1-GFP or GFP only (MOCK). b Primary 
pituitary tumor cells from three mutant rats were infected with the 
lentiviral vectors as in “a” and the level of Cyp11a1 was analyzed by 
qRT-PCR as indicated in the legend of Fig. 1, and is reported relative 
to the expression level in mock-transfected cells arbitrarily set to 100. 
c In samples parallel to “b”, cell proliferation was assessed 72 h after 
infection using the WST-1 assay. Data were analyzed independently 
with six replicates each and were expressed as the mean ± SEM. 
d In samples parallel to “c”, the expression of p21 was assessed by 
qRT-PCR as indicated in the legend of Fig. 1, and is reported rela-
tive to the expression level in mock-transfected cells arbitrarily set 
to 1. e Caspase 3/7 activity was measured in samples in parallel to 
“c” to monitor apoptosis in GH3 cells 72 h post-infection. *P < 0.05, 
**P < 0.01 versus MOCK
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Cyp11a1) to IsoQ (Fig. 7e). Altogether, these data pro-
vide indirect evidence that SF-1 is involved in regulating 
Cyp11a1 expression in gonadotroph cells.
Discussion
We recently demonstrated that PAs developing in MENX-
affected rats are pathologically similar to human gon-
adotroph adenomas [26]. The current study confirms this 
observation and shows that common genetic signatures 
exist between MENX-associated and human gonadotro-
pinomas. In addition, novel putative markers of human PAs 
were identified, suggesting that MENX-associated neo-
plasms may be exploited as to gene discovery.
In silico analysis of gene expression array data of human 
gonadotroph adenomas identified several genes differen-
tially expressed between tumors and normal pituitaries in 
both patients and MENX rats. An example of a gene down-
regulated in both rats and human PAs is Dlk1, encoding 
a non-canonical ligand of Notch. DLK1 was found to be 
selectively silenced in NFPAs but not in other types of PA 
[1, 5]. DLK1 is located in the DLK1/MEG3 imprinted locus 
on human chromosome 14q32.3 and MEG3, coding for a 
maternally imprinted long noncoding RNA with tumor sup-
pressive function, was also found to be specifically silenced 
through methylation in NFPAs, but not in other hypophy-
seal adenoma types [13]. In rat PAs, Gtl2 (Meg3) is down-
regulated (−1.95) but did not reach statistical significance.
Previous studies have compared human non-invasive 
and invasive/aggressive PAs with the aim to unveil the 
molecular mechanisms leading to an aggressive behavior 
and to identify markers predictive of invasiveness [12, 19, 
43]. Some genes or gene families we found up-regulated 
in MENX adenomas had previously been identified in 
human aggressive-invasive PAs, e.g., PTTG1, RACGAP1, 
CCNB1, CENPE, AURKB [12]. PTTG1, the homologue 
of yeast securin, controls the faithful separation of sister 
chromatids [46], while deregulated expression of centro-
some proteins (CENP) and Aurora kinases has been linked 
to defects in the mitotic machinery [41, 44]. Differential 
expression of the five genes mentioned above was observed 
Fig. 7  Co-localization of P450scc and SF-1 in rat PAs and reduc-
tion of Cyp11a1 expression following down-regulation or inhibition 
of SF-1 in gonadotroph cells. a Immunofluorescent staining with 
antibodies against P450scc (red) and SF-1 (green) was performed 
on FFPE pituitary tumor tissues from MENX mutant rats. Nuclei 
were counterstained with DAPI. The inset in MERGE shows the co-
localization of SF-1 and P450scc in rat tumor cells. Original mag-
nification: ×200; inset: ×400. b LβT2 cells were transfected with 
scrambled (MOCK) or siRNA oligos against the mouse Nr5a1 gene 
(siNr5a1). SF-1 and α-tubulin expression levels were assessed by 
Western blotting 24 and 48 h after transfection. c In samples parallel 
to “b”, Cyp11a1 expression level was assessed by qRT-PCR as indi-
cated in the legend of Fig. 1, and is reported relative to the expres-
sion level in mock-transfected cells arbitrarily set to 100. d LβT2 
cells were treated with different concentrations of the SF-1 inhibi-
tor IsoQ (0.1 M and 10 nM) or left untreated (CON). After 24 h, we 
determined Cyp11a1 expression levels as in “c”. e Primary pituitary 
tumor cells from mutant rats (n = 3) were incubated with IsoQ as in 
“d”. After 24 h, we assessed Cyp11a1 expression levels by qRT-PCR 
as in “c”. Data from primary cultures were analyzed independently 
with six replicates each and were expressed as the mean ± SEM. 
*P < 0.05, ***P < 0.001 versus MOCK or CON
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among benign, pre-malignant and malignant tumors, with a 
tendency to higher expression in the more malignant ones, 
with Pttg1 being expressed only in the latter group. Alto-
gether, these findings further support our initial hypothesis 
that MENX-associated PAs resemble aggressive tumors 
[26], and suggest that these lesions may be exploited to 
identify novel targets for specific therapies of aggressive 
PAs, currently orphan of specific molecular-targeted treat-
ment strategies. Moreover, our data further confirm the crit-
ical role of Pttg1 in pituitary tumorigenesis across different 
species and genetic backgrounds.
NUSAP1 is among the genes overexpressed in both 
rat and human PAs but has not so far been investigated 
in these tumors. We here report that 90 % of human gon-
adotroph adenomas express the NUSAP1 gene at high 
level. Concordantly, the number of cells immunoreactive 
for NuSAP was higher in tumors compared with normal 
pituitaries. NuSAP is a microtubule-associated protein 
that bundles and stabilizes microtubules thereby linking 
chromosomes to the mitotic spindle [35]. Recently, over-
expression of NUSAP1 has been found in various human 
cancers by array analysis, including glioblastomas, 
hepatocellular carcinomas, pancreatic adenocarcinoma 
(reviewed in [21]). The high expression of the NUSAP1 
gene has been associated with poor prognosis in mela-
noma patients [3], with a malignancy-risk genetic signa-
ture in breast cancer [4] and with recurrence in prostate 
cancer [15]. The study on prostate cancer has validated 
gene up-regulation seen by array analysis with immu-
nostaining for the NuSAP protein: tumors with Gleason 
grading scores ≥7 had more NuSAP-positive cells than 
tumors with lower scores [15]. We estimated the per-
centage of NuSAP-positive cells in human gonadotroph 
tumors (average 0.5 %, range 0.2–1 %) and found a cor-
relation with that of Ki-67-positive cells (average 1.2 %, 
range 0.5–2 %). Further studies are required to deter-
mine whether NuSAP labeling index correlates with the 
outcome of patients with PA and whether it provides a 
more accurate estimate of aggressive behavior than Ki67. 
Noteworthy, in addition to NUSAP1, our meta-analysis 
of human PA array data has identified the up-regulation 
of genes encoding other proteins playing a critical role 
in mitosis, mitotic spindle checkpoint and dynamics, 
or cytokinesis such as BUB1, CCNB1, CDC2, KIF4, 
KIF11, PRC1, in gonadotroph adenomas (Supplementary 
Table 2). These genes, if experimentally verified to be 
involved in PAs, may represent novel therapeutic targets 
for these tumors. While classical antimitotic compounds 
have limited clinical applications because of severe side 
effects, a new generation of drugs has been developed that 
targets kinesins (KIF proteins) and kinases with unique 
function in mitosis. These antitumor agents could be 
tested for the treatment of gonadotroph adenomas.
We observed that SF-1 and P450scc are co-expressed 
in PA cells of MENX-affected animals, and both siRNA-
mediated silencing of the Nr5a1 gene and treatment with 
the SF-1 inhibitor IsoQ resulted in the down-regulation 
of Cyp11a1 in rat primary tumor cells and in LβT2 gon-
adotroph cells. These results indicate that SF-1 regulates 
Cyp11a1 expression in gonadotroph cells. The transcrip-
tional regulation of Cyp11a1 in steroidogenic tissues is 
complex and involves the concerted action of several tis-
sue-specific trans-regulators such as SF-1, DAX1, TReP-
132, LBP, and GATA together with transcription factors 
having a more widespread expression, including AP-1, 
Sp1, and AP-2 [16]. Further studies are needed to identify 
the additional factors involved in the transcriptional regula-
tion of Cyp11a1 in PA cells.
CYP11A1 was up-regulated in 75 % of human gonado-
tropinomas and P450scc protein expression was high in 
these tumors, while barely detectable in normal pituitar-
ies. P450scc has been detected in the developing mouse 
at embryonic day 9.5 in Rathke’s pouch and at day 18.5 
in the pituitary primordium [17]. However, its potential 
role in pituitary development or in the adult pituitary has 
not been addressed. Here we show that Cyp11a1 plays a 
pro-proliferative role in Y1 adrenocortical cancer cells, 
but also in GH3 somatotroph adenoma cells and in rat 
primary pituitary gonadotroph cells. To the best of our 
knowledge, only two studies have so far addressed the 
putative role of Cyp11a1 in regulating cell proliferation 
or viability. The first one showed that overexpression of 
CYP11A1 in tumorigenic and non-tumorigenic mamma-
lian cell lines can either inhibit or enhance cell viability 
in a cell type-specific manner [7]. In cells sensitive to 
CYP11A1, gene overexpression led to decreased cell pro-
liferation through increase of p21 expression and induc-
tion of apoptosis [7]. The authors did not investigate the 
molecular processes associated with CYP11A1-mediated 
increase in cell proliferation. Based on our results, when 
the reduction of CYP11A1 level decreases cell prolifera-
tion (as seen in PA cells), both apoptosis and p21 expres-
sion are also involved, indicating that these are common 
pathways downstream of CYP11A1 signaling. In a more 
recent study, a truncated isoform of P450scc was found 
to suppress osteoblast proliferation in physiological con-
ditions [38]. Unlike the full length P450scc isoform, 
which is located in the mitochondria, this small isoform 
localizes to cytoplasm and nucleus, and might therefore 
be involved in still unidentified molecular pathways. Our 
studies show that Cyp11a1 plays a pro-proliferative role 
in adrenocortical cancer and PA cells, thereby provid-
ing additional evidence supporting a role for this gene in 
tumorigenesis.
In conclusion, we here provide experimental evi-
dence that the MENX animal model can be exploited as 
149Acta Neuropathol (2013) 126:137–150 
1 3
experimental tool to shed light into the pathomechanisms 
involved in human pituitary tumorigenesis. Several of the 
dysregulated genes here reported have never been associ-
ated with PAs, and may represent novel biomarkers for 
future clinical applications.
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